These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2822646)

  • 21. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
    Stratton CW; Liu C; Weeks LS
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.
    Blenkharn JI; Darrell JH
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):734-7. PubMed ID: 2550236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of six antibiotics against multiresistant staphylococci and other gram-positive cocci.
    Dixson S; Brumfitt W; Hamilton-Miller JM
    Eur J Clin Microbiol; 1985 Feb; 4(1):19-23. PubMed ID: 3157567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1982 Oct; 1(5):278-81. PubMed ID: 6223812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.
    Guenthner SH; Wenzel RP
    Antimicrob Agents Chemother; 1984 Aug; 26(2):268-9. PubMed ID: 6237606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus.
    Eng RH; Smith SM; Buccini FJ; Cherubin CE
    J Antimicrob Chemother; 1985 Feb; 15(2):201-7. PubMed ID: 3845078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
    Simon VC; Simon M
    Scand J Infect Dis Suppl; 1990; 72():14-9. PubMed ID: 2151061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LY146032: activity and resistance development in vitro.
    Mouton RP; Mulders SL
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.
    Debbia E; Pesce A; Schito GC
    Antimicrob Agents Chemother; 1988 Feb; 32(2):279-81. PubMed ID: 2834999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT; Dulworth JK; Brackman MA
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
    Roussel-Delvallez M; Wallet F; Barbiery P; Courcol RJ
    J Chemother; 1997 Feb; 9(1):5-8. PubMed ID: 9106011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.
    Foldes M; Munro R; Sorrell TC; Shanker S; Toohey M
    J Antimicrob Chemother; 1983 Jan; 11(1):21-6. PubMed ID: 6826485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.